Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

197 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Clinicogenomic Landscape of Induction Failure in Childhood and Young Adult T-Cell Acute Lymphoblastic Leukemia.
O'Connor D, Demeulemeester J, Conde L, Kirkwood A, Fung K, Papaleonidopoulou F, Bloye G, Farah N, Rahman S, Hancock J, Bateman C, Inglott S, Mee J, Herrero J, Van Loo P, Moorman AV, Vora A, Mansour MR. O'Connor D, et al. Among authors: farah n. J Clin Oncol. 2023 Jul 1;41(19):3545-3556. doi: 10.1200/JCO.22.02734. Epub 2023 Apr 25. J Clin Oncol. 2023. PMID: 37098241 Free PMC article.
Prognostic impact of the absence of biallelic deletion at the TRG locus for pediatric patients with T-cell acute lymphoblastic leukemia treated on the Medical Research Council UK Acute Lymphoblastic Leukemia 2003 trial.
Farah N, Kirkwood AA, Rahman S, Leon T, Jenkinson S, Gale RE, Patrick K, Hancock J, Samarasinghe S, Linch DC, Moorman AV, Goulden N, Vora A, Mansour MR. Farah N, et al. Haematologica. 2018 Jul;103(7):e288-e292. doi: 10.3324/haematol.2017.185801. Epub 2018 Mar 8. Haematologica. 2018. PMID: 29519867 Free PMC article. No abstract available.
EZH2-Deficient T-cell Acute Lymphoblastic Leukemia Is Sensitized to CHK1 Inhibition through Enhanced Replication Stress.
León TE, Rapoz-D'Silva T, Bertoli C, Rahman S, Magnussen M, Philip B, Farah N, Richardson SE, Ahrabi S, Guerra-Assunção JA, Gupta R, Nacheva EP, Henderson S, Herrero J, Linch DC, de Bruin RAM, Mansour MR. León TE, et al. Among authors: farah n. Cancer Discov. 2020 Jul;10(7):998-1017. doi: 10.1158/2159-8290.CD-19-0789. Epub 2020 Apr 29. Cancer Discov. 2020. PMID: 32349972 Free PMC article.
Activation of the LMO2 oncogene through a somatically acquired neomorphic promoter in T-cell acute lymphoblastic leukemia.
Rahman S, Magnussen M, León TE, Farah N, Li Z, Abraham BJ, Alapi KZ, Mitchell RJ, Naughton T, Fielding AK, Pizzey A, Bustraan S, Allen C, Popa T, Pike-Overzet K, Garcia-Perez L, Gale RE, Linch DC, Staal FJT, Young RA, Look AT, Mansour MR. Rahman S, et al. Among authors: farah n. Blood. 2017 Jun 15;129(24):3221-3226. doi: 10.1182/blood-2016-09-742148. Epub 2017 Mar 7. Blood. 2017. PMID: 28270453 Free PMC article.
Pre-Clinical Evaluation of the Hypomethylating Agent Decitabine for the Treatment of T-Cell Lymphoblastic Lymphoma.
Provez L, Putteman T, Landfors M, Roels J, Reunes L, T'Sas S, Van Loocke W, Lintermans B, De Coninck S, Thenoz M, Sleeckx W, Maćkowska-Maślak N, Taghon T, Mansour MR, Farah N, Norga K, Vandenberghe P, Kotecha RS, Goossens S, Degerman S, De Smedt R, Van Vlierberghe P. Provez L, et al. Among authors: farah n. Cancers (Basel). 2023 Jan 20;15(3):647. doi: 10.3390/cancers15030647. Cancers (Basel). 2023. PMID: 36765607 Free PMC article.
Concerns about how to use established minimal residual disease monitoring in the treatment of NPM1-mutant acute myeloid leukaemia (AML) following reduced intensity chemotherapy protocols for AML given as a result of the COVID-19 pandemic.
Farah N, Burt R, Ibrahim AR, Baker R, Kottaridis PD. Farah N, et al. Br J Haematol. 2020 Aug;190(4):e208-e210. doi: 10.1111/bjh.16985. Epub 2020 Jul 26. Br J Haematol. 2020. PMID: 32609881 Free PMC article. No abstract available.
197 results